Cervical Cancer and Human Papilloma Virus

Consistent with this view, 13 months ago, the Advisory Committee on Immunization Practices of the Centers for Disease Control and Prevention recommended the use of 9-valent HPV vaccine *Trademark: Gardasil®9 (Merck & Co., Inc., West Point, Pennsylvania).; it is now the third HPV vaccine availabl...

Full description

Saved in:
Bibliographic Details
Published in:Clinical therapeutics 2016-03, Vol.38 (3), p.429-430
Main Author: Shader, Richard I., MD
Format: Article
Language:English
Subjects:
Cervical cancer
Disease prevention
Human papillomavirus
Internal Medicine
Medical Education
Mouth
Vaccines
Citations: Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Consistent with this view, 13 months ago, the Advisory Committee on Immunization Practices of the Centers for Disease Control and Prevention recommended the use of 9-valent HPV vaccine *Trademark: Gardasil®9 (Merck & Co., Inc., West Point, Pennsylvania).; it is now the third HPV vaccine available in the United States, and it protects against nine strains of the virus.2 Unfortunately, this effective strategy for HPV prevention is still not as widely in use as it should be in the United States or elsewhere in the world.3 This is the second time our Update theme focuses on cervical cancer, underscoring the challenge of tackling this disease. Better treatment outcomes may be achieved through the adjunctive use of antibodies, such as programmed cell death inhibitors (PD-1 and PD-L1 inhibitors), agents that allow the immune system to reduce or halt cancer growth.
ISSN:0149-2918
1879-114X
DOI:10.1016/j.clinthera.2016.02.017